SPY
769.86
+0.03%
QQQ
749.55
−0.00%
BTC/USD
84,754.24
+0.30%
DIA
511.70
+0.12%
GLD
380.52
+0.10%
TLT
77.53
+0.06%
US
Sign in
Register
My Account
Benzinga
Markets & News
Markets
Stocks & Sectors
Stocks
Ratings & Research
Ratings
Trading
Trading
Screeners & Lists
Screeners
Learn
Learn
Premium
Premium Services
Markets & News
Breaking headlines, the trading day, and the calendars that move it.
Stocks & Sectors
Research any ticker, then drill into sectors, ratings, and options.
Ratings & Research
Wall Street calls, insider moves, and Benzinga's own stock rankings.
Trading
Options flow, trade calculators, and ideas for active traders.
Screeners & Lists
Filter the market your way, or start from a curated list.
Learn
Pick a broker, grow your savings, and protect what you've built.
Premium Services
Edge
Ratings, signals & screens
Pro
Real-time news & data terminal
Research
Trade alerts & newsletters
APIs
Market data licensing
All sections
ResMed Inc
RMD
NYSE
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$218.89
-2.26
-1.02%
Last update: Oct 2, 5:55 PM
$218.89
-2.26
-1.02%
Get Report
Overview
News
Earnings Forecast
Events
Price Targets
Financials
Sentiment
Ownership
Dividends
Compare
Options
Stock Report
Privacy Manager
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga
Edge
Benzinga
Research
Benzinga
Pro
Logout
ResMed Financials
ResMed (RMD) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
ResMed Q4 Adj. EPS $2.95 Beats $2.89 Estimate, Sales $1.464B Beat $1.459B Estimate
ResMed (NYSE:RMD) reported quarterly earnings of $2.95 per share which beat the analyst consensus estimate of $2.89 by 2.08 percent. This is a 15.69 percent increase over earnings of $2.55 per share from the same period
Benzinga Newsdesk
Jim Cramer Warns This Market Is Far More Brutal Than Dot-Com Bubble Era: 'The Difference Between Now And 1999 Is...'
Jim Cramer says investors are aggressively favoring AI stocks while heavily punishing companies that disappoint Wall Street.
Tanya Rawat
PRO
ResMed Q3 Adj. EPS $2.86 Beats $2.80 Estimate, Sales $1.431B Beat $1.419B Estimate
ResMed (NYSE:RMD) reported quarterly earnings of $2.86 per share which beat the analyst consensus estimate of $2.80 by 2.14 percent. This is a 20.68 percent increase over earnings of $2.37 per share from the same period
Benzinga Newsdesk
Earnings Scheduled For April 30, 2026
Benzinga Insights
Analysts Maintain Bull Case On ResMed Despite Competition Concerns
ResMed beat earnings and revenue estimates as sales rose 11% and margins expanded. Analysts backed long-term growth and raised price targets despite competition concerns.
Vandana Singh
Insights into ResMed Q2 Earnings
Benzinga Insights
